SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "TQA3038 (siRNA)" COMPLETED PHASE I CLINICAL STUDY
Apr 25 06:03 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Apr 19 06:09 ET
SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN
Apr 19 05:02 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "ROVADICITINIB (TQ05105)" OBTAINED POSITIVE RESULTS IN KEY CLINICAL RESEARCH FOR REGISTRATION
Apr 18 07:27 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Apr 17 05:09 ET
SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN
Apr 16 04:35 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Apr 15 04:59 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Apr 12 05:22 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - PRESENTATION OF THE PHASE II CLINICAL STUDY DATA ON KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)"
Apr 10 18:04 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - DATA OF 6 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES", "TQB2916 (CD40 AGONIST)" AND "FHND6091 (PROTEASOME INHIBITOR)" WERE PRESENTED AT 2024 AACR
Apr 10 08:02 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Apr 8 05:52 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC PARTNERSHIP WITH BOEHRINGER INGELHEIM ON INNOVATIVE ONCOLOGY PORTFOLIO IN CHINA
Apr 7 19:59 ET
SINO BIOPHARM: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
Apr 1 21:56 ET
SINO BIOPHARM: FINAL DIVIDEND FOR 2023
Mar 28 05:03 ET
SINO BIOPHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Mar 28 04:31 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "IOPROMIDE INJECTION"
Mar 24 18:11 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - UPDATE ON DEVELOPMENT PROGRESS OF MASH PRODUCTS "LANIFIBRANOR" AND "TQA2225"
Mar 15 05:56 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - DATA OF PHASE II CLINICAL STUDY OF KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" WILL BE PRESENTED AT 2024 AACR
Mar 13 04:34 ET
SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - DATA OF 5 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES" AND "TQB2916 (CD40 AGONIST)" WILL BE PRESENTED AT 2024 AACR
Mar 11 06:56 ET
SINO BIOPHARM: NOTIFICATION OF BOARD MEETING
Mar 1 03:34 ET
No Data
No Data